Profound Medical Corp. (TSX:PRN)

Market Cap	316.11M +0.9%
Revenue (ttm)	19.91M +67.9%
Net Income	-54.80M
EPS	-1.89
Shares Out	36.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,675
Average Volume	19,811
Open	8.51
Previous Close	8.77
Day's Range	8.51 - 9.01
52-Week Range	5.23 - 12.40
Beta	0.36
RSI	32.93
Earnings Date	Mar 13, 2026

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prosta...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Arun Menawat
• Employees: 142
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: PRN

Financial Performance

In 2024, Profound Medical's revenue was $10.68 million, an increase of 48.35% compared to the previous year's $7.20 million. Losses were -$27.82 million, -1.79% less than in 2023.

Financial numbers in USD